ArticleCureus2025
Eclampsia and Neonatal Loss in a Patient With Primary Antiphospholipid Syndrome, Factor V Leiden, and Methylenetetrahydrofolate Reductase (MTHFR) Mutations: A Rare Thrombophilic Triad.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by an increased risk of thrombosis and pregnancy complications, including placental insufficiency, preeclampsia, and fetal loss. The coexistence of APS with both factor V Leiden and methylenetetrahydrofolate reductase (MTHFR) mutations is exceptionally rare and may further elevate the risk of adverse outcomes. A 23-year-old primigravida developed eclampsia at eight months' gestation and underwent an emergency cesarean section; unfortunately, her newborn died a few days later. Laboratory evaluation confirmed APS with a positive lupus anticoagulant, anticardiolipin, and anti-β2 glycoprotein I, as well as the presence of factor V Leiden and MTHFR mutations. Hydroxychloroquine, aspirin, and low-molecular-weight heparin therapy were initiated. This case should encourage physicians to broaden their initial screening laboratory tests and consider implementing more comprehensive testing in patients who present with early and severe pre-eclampsia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.